SCHEMBL3688705

SCHEMBL3688705

CON(C)C(=O)c1cccc(Cl)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.48
CYP11B2 P19099 2/20 0.48
SLC6A3 Q01959 2/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
POLB P06746 1/20 0.42
KAT6A Q92794 1/20 0.40
MLYCD O95822 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
NOTUM Q6P988 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 1/20 0.38
ENPP2 Q13822 1/20 0.37
KMT2A Q03164 1/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
IDO1 P14902 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653569 0.85 TSHR (0.52) SLC6A3SLC6A2SLC6A4POLBMLYCD
SCHEMBL308205 0.84 POLB (0.59) POLBTSHRHPGDKMT2ACES2
SCHEMBL15761206 0.83 UTS2R (0.43) SLC6A3SLC6A2SLC6A4POLBPKM
SCHEMBL1585165 0.83 CYP11B1 (0.48) CYP11B1CYP11B2SLC6A3SLC6A2SLC6A4
SCHEMBL4026691 0.83 CES2 (0.55) CYP11B1CYP11B2KAT6AMLYCDTRPM8
SCHEMBL307136 0.82 MLYCD (0.42) CYP11B1CYP11B2SLC6A3POLBMLYCD
SCHEMBL18436192 0.82 POLB (0.41) CYP11B1CYP11B2SLC6A3POLBMLYCD
SCHEMBL13694021 0.82 TSHR (0.42) CYP11B1CYP11B2SLC6A3POLBPKM
SCHEMBL8577021 0.82 POLB (0.41) SLC6A3POLBNOTUMPKMRAB9A
SCHEMBL17604738 0.82 POLB (0.41) CYP11B1CYP11B2SLC6A3POLBMLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2880017-B1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES INC (US) 2016-10-05 EP disclosed
EP-2880017-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS Gilead Sciences, Inc. (US) 2015-06-10 EP disclosed
US-8877931-B2 Process and intermediates for preparing integrase inhibitors GILEAD SCIENCES, INC. (US) 2014-11-04 US disclosed
WO-2014022707-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-02-06 WO disclosed
US-20140039194-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-02-06 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 WO disclosed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140039194-A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS TYMS, TYMP, POLB CYP11B1 186/4885CYP11B2 262/4885SLC6A3 4184/4885
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR CYP11B1 864/4885CYP11B2 868/4885SLC6A3 2448/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 CYP11B1 902/4885CYP11B2 837/4885SLC6A3 2644/4885
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG CYP11B1 154/4885CYP11B2 117/4885SLC6A3 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.